Oertel, Michael http://orcid.org/0000-0002-2786-7013
Ziepert, Marita
Frontzek, Fabian http://orcid.org/0000-0003-1705-3638
Nacke, Nina
Altmann, Bettina
Nickelsen, Maike
Glass, Bertram http://orcid.org/0000-0003-2583-6333
Poeschel, Viola
Ruebe, Christian
Lenz, Georg http://orcid.org/0000-0002-4728-1693
Schmitz, Norbert http://orcid.org/0000-0003-4938-7528
Eich, Hans Theodor
Article History
Received: 22 November 2023
Revised: 7 March 2024
Accepted: 12 March 2024
First Online: 27 March 2024
Competing interests
: No compensations or grants were directly related to the submitted analysis. BG received compensation to his institution for consultancy and membership by Kite, BMS, Novartis, Roche, Abbvie, Janssen, Pfizer and Miltenyi and research grants from Roche. VP received compensation in favor of the German lymphoma alliance by BMS, EUSA Pharma, Janssen-Cilag GmbH, BeiGene Germany GmbH, Gilead Sciences GmbH Research and also research funding by BMS, Roche, Talon Therapeutics, Spectrum Pharmaceuticals, Amgen, Acrotech Biopharma, Abbvie, Chugai, Deutsche Krebshilfe. GL has participated in a consulting or advisory role for Abbvie, ADC Therapeutics, Amgen, AstraZeneca, Bayer, BMS, Constellation, Gilead, Genase, Genmab, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, Morphosys, NanoString, Novartis, PentixaPharm, Roche, Sobi and Takeda, has been on a speaker’s bureau for Bayer, Celgene, Gilead, Janssen and Roche, has received research funding from AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen and Roche. HTE has received research funding by the German Cancer Aid.